AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Analysis from TACTICS-TIMI 18 trial published.
2004 APR 1 - (NewsRx.com & NewsRx.net) -- Guilford Pharmaceuticals, Inc., (GLFD) announced the publication of new data in the journal, Circulation, demonstrating that the addition of AGGRASTAT Injection (tirofiban hydrochloride), along with aspirin, heparin, and coronary stenting, coupled with an aggressive, early intervention treatment strategy for acute coronary syndrome (ACS), was associated with a statistically significant decrease in the rate of death, myocardial infarction, or rehospitalization for patients with ACS (p
The article, entitled "Implications of Upstream Glycoprotein IIb/IIIa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/Non-ST- Elevation Myocardial Infarction," compares data from two previously published trials, TIMI IIIB and TACTICS-TIMI 18.
Marc S. Sabatine, MD, MPH, cardiovascular division, Brigham and Women's Hospital, commented, "In the past decade, we have seen a continued evolution in the early care of patients presenting with ischemic heart disease. By comparing results of TACTICS-TIMI 18 with the earlier TIMI IIIB trial, we were able to identify and underscore the impact and importance of these new therapies, particularly GP IIb/IIIa inhibition."
Chris Cannon, MD, cardiovascular division, Brigham and Women's Hospital, stated, "These data provide additional compelling evidence that upstream utilization of AGGRASTAT effectively reduces the incidence of major adverse cardiac events in patients with ACS. Approximately two-thirds of intermediate-to-high-risk ACS patients currently do not receive treatment with a GP IIb/IIIa inhibitor upstream, despite ... guidelines recommending the use of GP IIb/IIIa inhibitors as part of an early invasive approach. These new ...
- Stenting and/or GP IIb/IIIa blockade effective during PCI.
- Newspaper article from: Medical Devices & Surgical Technology Week December 28, 2003 700+ words
...coronary intervention (PCI). "Stenting and GP IIb/IIIa inhibition are promising adjunctive...and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment...Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7...
- GP IIb/IIIa Inhibitors Safe With Enoxaparin.
- Magazine article from: Family Practice News JANCIN, BRUCE October 15, 2000 700+ words
...molecular-weight heparins and glycoprotein (GP) IIb/IIIa inhibitors have separately demonstrated...prior large clinical trials that involved GP IIb/IIIa antagonists, the incidence of such...significant differences among the three GP IIb/IIIa antagonists, Dr. Ferguson noted...
- NICE 3 ESTABLISHES SAFETY OF ENOXAPARIN AND GP IIB/IIIA THERAPY FOR PATIENTS...
- Press release article from: PR Newswire August 30, 2000 700+ words
...weight heparin) with commercially available GP IIb/IIIa antagonists (potent new antiplatelet...other powerful antiplatelet drugs (such as GP IIb/IIIa antagonists) and how to proceed...can safely be combined with any of the GP IIb/IIIa antagonists, and also suggest that...
- NICE 3 Establishes Safety of Enoxaparin and GP IIb/IIIa Therapy for Patients...
- Press release article from: PR Newswire August 30, 2000 700+ words
...weight heparin) with commercially available GP IIb/IIIa antagonists (potent new antiplatelet...other powerful antiplatelet drugs (such as GP IIb/IIIa antagonists) and how to proceed...can safely be combined with any of the GP IIb/IIIa antagonists, and also suggest that...
- COR Therapeutics' Once-A-Day Oral GP IIb-IIIa Inhibitor Continues to Show...
- Press release article from: Business Wire November 8, 1999 700+ words
...COR Therapeutics' (Nasdaq:CORR) oral GP IIb-IIIa inhibitor, cromafibarted. Cromafiban...significantly from those of other oral GP IIb-IIIa inhibitors for which unsatisfactory...Based upon successful trials of intravenous GP IIb-IIIa inhibitors in the prevention of...
- Angiomax(R) (bivalirudin) Monotherapy Superior to Heparins Plus GP IIb/IIIa...
- Press release article from: Business Wire March 12, 2006 700+ words
...unfractionated or low-molecular weight) plus GP IIb/IIIa inhibitor control arm (Arm A...which patients received Angiomax plus a GP IIb/IIIa inhibitor, the endpoints were also...ACUITY trial demonstrated that Angiomax and GP IIb/IIIa inhibitors can be combined safely...
- Searle Announces Launch of Phase III EXCITE Trial on Xemilofiban -- Will Assess...
- Press release article from: PR Newswire November 10, 1997 700+ words
...benefits with sustained anti-platelet therapy with an oral GP IIb/IIIa receptor antagonist, in the largest prospective interventional...increased risk for cardiac events. Currently, intravenous GP IIb/IIIa therapy -- administered over a period of several hours...
- Here are criteria for GP IIb/IIIa inhibitors.
- Magazine article from: ED Nursing September 1, 2002 700+ words
Here are criteria for GP IIb/IIIa inhibitors The following are indications and contraindications for glycoprotein IIb/IIIa inhibitors: Indications: 1...
